|
1
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takeda M, Okamoto I, Sakai K, Kawakami H,
Nishio K and Nakagawa K: Clinical outcome for EML4-ALK-positive
patients with advanced non-small-cell lung cancer treated with
first-line platinum-based chemotherapy. Ann Oncol. 23:2931–2936.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takeda M, Okamoto I and Nakagawa K: Pooled
safety analysis of EGFR-TKI treatment for EGFR mutation-positive
non-small cell lung cancer. Lung Cancer. 88:74–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park K, Tan E, Zhang L, Hirsh V, O'Byrne
K, Boyer M, Yang JC, Mok T, Kim M, Massey D, et al: Afatinib vs
gefitinib as first-line treatment for patients with advanced
non-small cell lung cancer harboring activating EGFR mutations:
Results of the global, randomized, open-label, Phase IIb trial
LUX-Lung 7. Ann Oncol. 26:(Suppl 9). ix161–ix162. 2015. View Article : Google Scholar
|
|
14
|
Urata Y, Katakami N, Morita S, Kaji R,
Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D,
et al: Randomized phase III study comparing gefitinib with
erlotinib in patients with previously treated advanced lung
adenocarcinoma: WJOG 5108L. J Clin Oncol. pii:JCO634154. 2016.
|
|
15
|
Nelson V, Ziehr J, Agulnik M and Johnson
M: Afatinib: Emerging next-generation tyrosine kinase inhibitor for
NSCLC. Onco Targets Ther. 6:135–143. 2013.PubMed/NCBI
|
|
16
|
Li J, Karlsson MO, Brahmer J, Spitz A,
Zhao M, Hidalgo M and Baker SD: CYP3A phenotyping approach to
predict systemic exposure to EGFR tyrosine kinase inhibitors. J
Natl Cancer Inst. 98:1714–1723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan AR, Yang X, Hewitt SM, Berman A,
Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, et
al: Evaluation of biologic end points and pharmacokinetics in
patients with metastatic breast cancer after treatment with
erlotinib, an epidermal growth factor receptor tyrosine kinase
inhibitor. J Clin Oncol. 22:3080–3090. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzumura T, Kimura T, Kudoh S, Umekawa K,
Nagata M, Matsuura K, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, et
al: Reduced CYP2D6 function is associated with gefitinib-induced
rash in patients with non-small cell lung cancer. BMC Cancer.
12:5682012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takimoto T, Kijima T, Otani Y, Nonen S,
Namba Y, Mori M, Yokota S, Minami S, Komuta K, Uchida J, et al:
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Clin Lung Cancer. 14:502–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takeda M, Okamoto I, Tsurutani J, Oiso N,
Kawada A and Nakagawa K: Clinical impact of switching to a second
EGFR-TKI after a severe AE related to a first EGFR-TKI in
EGFR-mutated NSCLC. Jpn J Clin Oncol. 42:528–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
